8-K: Liquidia Secures Final $32.5 Million in Funding, Modifies Payment Schedule with HCR

Liquidia Corporation has secured the remaining $32.5 million under its Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, modifying the payment schedule and extending the payment term.

Summary

• Liquidia Corporation's subsidiary, Liquidia Technologies, entered into a Fifth Amendment to its Revenue Interest Financing Agreement with HealthCare Royalty Partners IV (HCR).
• This amendment releases the remaining $32.5 million of the $100 million total financing, moving it from the third and fourth tranches to the second tranche.
• Following this amendment, HCR will have funded a total of $67.5 million under the second tranche, and the third and fourth tranches are eliminated.
• The payment schedule will remain fixed and will not convert to a tiered royalty based on net revenue after the first commercial sale of YUTREPIA.
• The payment schedule has been modified, extending the expected termination of payments from 2029 to 2031.
• A one-time fixed payment of $23.8 million, originally due in July 2025, has been deferred into two equal payments due in January 2026 and July 2026.
• The aggregate payments to HCR are capped at 175% of the total amounts advanced.
• There is a potential true-up payment if HCR's internal rate of return is less than 16% on the date the cap is reached for the newly advanced funds, compared to 18% for previously advanced funds.
• The funding of the additional $32.5 million is contingent upon Liquidia receiving at least $50 million in gross proceeds from the sale of its common stock.

Sentiment

Score: 7

Explanation: The document indicates a positive development in securing the remaining funding, but the requirement to raise $50 million through a stock sale and the extended payment term temper the overall sentiment.

Positives

• Liquidia has secured the remaining $32.5 million in non-dilutive capital, completing the $100 million financing agreement with HCR.
• The fixed payment schedule provides predictability for future cash outflows.
• The deferral of the $23.8 million payment provides short-term financial relief.
• The cap on total payments to HCR limits the overall cost of the financing.
• The true-up payment threshold for the new funds is lower at 16% compared to 18% for previous funds, potentially reducing the risk of a true-up payment.

Negatives

• The payment term has been extended to 2031, increasing the long-term financial obligation.
• The company is required to raise at least $50 million from a stock sale to receive the final $32.5 million in funding, which could be dilutive to existing shareholders.
• The true-up payment, while at a lower threshold, still represents a potential additional cost if HCR's return is below 16%.

Risks

• The company's ability to raise $50 million from a stock sale is not guaranteed and could impact the funding.
• The extended payment term to 2031 increases the long-term financial burden on the company.
• The potential true-up payment could add to the overall cost of the financing if HCR's return is below the 16% threshold.
• The company is reliant on the success of YUTREPIA to meet its payment obligations.

Future Outlook

The company has secured the remaining funding under the agreement, but is now reliant on the success of YUTREPIA to meet its payment obligations. The company must also raise $50 million from a stock sale to receive the final tranche of funding.

Management Comments

• The document does not contain any direct quotes from management.

Industry Context

This type of revenue interest financing is common in the biotech industry, where companies often seek non-dilutive funding to support drug development and commercialization. The modification of the payment schedule and deferral of payments are also common strategies to manage cash flow and financial obligations.

Comparison to Industry Standards

• Revenue interest financing is a common method for biotech companies to raise capital, particularly for those with promising late-stage assets.
• Companies like Royalty Pharma and DRI Capital are major players in the royalty financing space, often providing capital to companies in exchange for a share of future revenues.
• The 175% cap on total payments is a typical feature in these types of agreements, limiting the overall cost of capital.
• The internal rate of return threshold for true-up payments is also a standard practice, ensuring that the lender achieves a minimum return on their investment.
• The specific terms of this agreement, such as the 16% threshold for the new funds, are specific to the negotiation between Liquidia and HCR.

Stakeholder Impact

• Shareholders may experience dilution if the company raises capital through a stock sale.
• Creditors will be impacted by the extended payment schedule.
• The company's ability to meet its financial obligations will depend on the success of YUTREPIA.

Next Steps

• Liquidia needs to complete a stock sale to receive the final $32.5 million in funding.
• Liquidia will need to make the deferred payments in January and July 2026.
• Liquidia will need to meet the payment obligations under the extended schedule until 2031.
• A copy of the Fifth Amendment will be filed as an amendment to this report on Form 8-K or with a new Form 8-K.

Key Dates

Keywords

Liquidia, Healthcare Royalty Partners, Revenue Interest Financing, YUTREPIA, Non-dilutive financing, Capital raise, Fixed payment schedule, Tranche, Funding, Amendment